Drugs / Ibutamoren
Ibutamoren
also known as
MK-0677 · ibutamoren mesylate · MK-677 · Ibutamoren mesilate · Ibutamoreno · L-163,191 · Merck L-163 191
Small molecule targets GHSR via activation
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00474279 | Jul 1998 → Jun 2004 | — | University of Virginia | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT01343641 | Mar 2009 → Apr 2010 | chronic kidney disease | University of Virginia | Withdrawn | No outcome recorded |
| Phase 2 | NCT00128115 | Sep 2005 → Aug 2007 | — | Merck Sharp & Dohme LLC | Terminated | Mixed |
| Phase 2 | NCT00074529 | Oct 2003 → Jan 2006 | Alzheimer disease | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase not applicable1 trial · 1 met primary | ||||||
| — | NCT00395291 | Aug 2006 → Jan 2009 | end stage renal failure | University of Virginia | Completed | Met primary |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT00116129 Comparator | Jul 2005 → Jan 2008 | fibromyalgia | Bennett, Robert, M.D. | Completed | No outcome recorded |
Evidence & citations 12 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ibutamoren | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00116129 ↗ |
| Known as | Ibutamoren mesilate | ChEMBL registry synonym — accepted as the source's own label CHEMBL13817 ↗ |
| Known as | ibutamoren mesylate | “MK-0677 (ibutamoren mesylate) for the treatment of patients recovering from hip fracture: a multicenter, randomized, placebo-controlled phase IIb study.” PMID 21067829 ↗ Nov 20101“Ibutamoren Mesylate (MK-0677)” NCT00116129 ↗ |
| Known as | Ibutamoreno | ChEMBL registry synonym — accepted as the source's own label CHEMBL13817 ↗ |
| Known as | L-163,191 | ChEMBL registry synonym — accepted as the source's own label CHEMBL13817 ↗ |
| Known as | Merck L-163 191 | “The oral agent MK-677 is spiropiperidine, Merck L-163 191, GH secretagogue ghrelin mimetic which increases GH and IGF-I secretion, fat free mass and energy expenditure76-79.” NCT01343641 ↗ |
| Known as | MK-0677 | “A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of MK-0677 25 mg in Slowing the Progression of Alzheimer's Disease” NCT00074529 ↗6“MK-0677 (ibutamoren mesylate) for the treatment of patients recovering from hip fracture: a multicenter, randomized, placebo-controlled phase IIb study.” PMID 21067829 ↗ Nov 2010 “Ibutamoren Mesylate (MK-0677)” NCT00116129 ↗ |
| Known as | MK-677 | “The oral agent MK-677 is spiropiperidine, Merck L-163 191, GH secretagogue ghrelin mimetic which increases GH and IGF-I secretion, fat free mass and energy expenditure76-79.” NCT01343641 ↗ |
| Action | Activate | “acts on the growth hormone secretagogue receptor in the anterior pituitary to stimulate the release of growth hormone.” NCT00116129 ↗1“Ghrelin receptor agonist” CHEMBL13817 ↗ |
| Modality | Small molecule | — CHEMBL13817 ↗ |
| Route | Oral | “orally administered growth hormone secretagogue” NCT00116129 ↗ |
| Target | GHSR | “Ghrelin receptor agonist” CHEMBL13817 ↗ |